NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
43
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,826.40 | 15.50 | -0.18% |
CAC 40 | 7,712.63 | 16.36 | 0.21% |
DAX 40 | 23,960.52 | 173.07 | 0.73% |
Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
FTSE 100 | 8,836.19 | 13.28 | 0.15% |
HKSE | 23,887.83 | 28.23 | -0.12% |
NASDAQ | 20,601.10 | 207.97 | 1.02% |
Nikkei 225 | 39,587.68 | 223.20 | -0.56% |
NZX 50 Index | 12,764.95 | 1.65 | -0.01% |
S&P 500 | 6,279.35 | 51.93 | 0.83% |
S&P/ASX 200 | 8,589.30 | 13.70 | -0.16% |
SSE Composite Index | 3,473.13 | 0.81 | 0.02% |